Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction

NCT06739668 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction. Total study duration will be 8 weeks, including 4 weeks of treatment and 4 weeks of untreated follow up.

Interventions

  • DEVICE Sham Device
  • DEVICE Pascal device

Study Locations (1)

New York

  • The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE) — New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-12-19
Est. Completion 2025-12-01
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06739668

The ClinicalTrials.gov registry entry for NCT06739668 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 946 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions — of which Sham Device is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06739668 reports 1 study location spanning 1 distinct geographic area — top geographies include New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06739668 about?

NCT06739668 is a clinical study titled "Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction". The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PAS...

What is the current status of trial NCT06739668?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2024-12-19. Estimated completion is 2025-12-01.

What conditions does trial NCT06739668 study?

This clinical trial studies the following conditions: Cognitive Dysfunction, Post-Acute COVID-19 Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06739668?

The interventions under investigation include: Sham Device (DEVICE), Pascal device (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06739668?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 946 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06739668 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial